HBV focus Arbutus Biopharma, formed from the OnCore Tekmira merger, specializes in curing chronic hepatitis B virus (HBV). This presents a sales opportunity to partner with Arbutus on HBV-targeted solutions, research collaborations, and platform technologies aligned with chronic infectious disease management.

Strategic partnerships Recent high-profile collaborations and settlements, including engagements with Moderna and a global settlement potential, indicate a readiness to explore co-development, licensing, and strategic alliances that could expand product reach and accelerate clinical programs.

Legal and IP leverage Active patent enforcement actions against major players (Pfizer, BioNTech) and ongoing litigation initiatives suggest a market where robust IP support and licensing negotiations could create opportunities for complementary technologies, companion diagnostics, or cross-licensing deals.

Funding and growth Small revenue base with ongoing funding and a recently appointed CEO signals a company in growth mode and open to capital-efficient collaborations, sponsorships of research, or contract research services to advance late-stage HBV programs.

Thought leadership Launch of a Scientific Advisory Board and active presence at major conferences (AASLD, EASL) indicate a push to validate programs and attract partnerships; sales teams can leverage their published data and thought leadership to approach Arbutus with co-marketing and joint-education opportunities.